ArriVent BioPharma Inc Dossier - Source-backed chat

ArriVent BioPharma Inc

AVBPNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.24

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $30.28Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $1.5B

Enterprise Value $1.3B

Shares Outstanding 50.4M diluted

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

ArriVent BioPharma is a clinical-stage biopharmaceutical company with a highly de-risked, late-stage lead asset, firmonertinib, targeting high-value EGFR-mutant non-small cell lung cancer (NSCLC) populations. By focusing on clinical execution and in-licensing rather than early-stage discovery, ArriVent maintains a capital-efficient model. The upcoming mid-2026 Phase 3 FURVENT trial readout represents a major near-term catalyst that could significantly re-rate the stock, supported by a robust cash runway extending into late 2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$40.00

Mean target$44.40

High · most bullish analyst$50.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$25.2520%

The FURVENT trial fails to show a statistically significant or clinically meaningful PFS benefit over standard chemotherapy, or reveals unexpected safety concerns. This severely damages the commercial viability of firmonertinib outside China, leaving the company dependent on its earlier-stage ADC pipeline and causing a significant downward re-rating.

Base CaseCentral scenario

$44.4050%

Matches the consensus mean

The Phase 3 FURVENT trial meets its primary endpoint with clinically meaningful PFS improvement over chemotherapy, supporting a standard regulatory submission path. Firmonertinib is recognized as a competitive treatment option in a crowded market, while the ADC pipeline advances steadily into early-stage clinical trials.

Bull CaseUpside scenario

$50.0030%

The Phase 3 FURVENT trial delivers outstanding progression-free survival (PFS) data that establishes firmonertinib as a best-in-class first-line therapy for EGFR exon 20 insertion mutant NSCLC, leading to rapid global regulatory approvals and commercial adoption. Concurrently, the ALPACCA trial in PACC mutations accelerates, and the ADC pipeline (ARR-002 and ARR-217) shows strong early clinical efficacy.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Lead asset firmonertinib is already approved and commercially successful in China, significantly de-risking its biological efficacy and safety profile.
Strong financial position with $326.4 million in cash and short-term investments as of March 31, 2026, providing a runway into 4Q 2027.
Targeting high-value, underserved oncology niches (EGFR exon 20 insertions and PACC mutations) with Breakthrough Therapy Designation.
Capital-efficient business model focused on clinical development and global commercialization of in-licensed assets.

Key Investment Risks

High asset concentration risk, as the company's valuation is heavily tied to the clinical and commercial success of firmonertinib.
Intense competition in the EGFR-mutant NSCLC space from established blockbusters (e.g., AstraZeneca's Tagrisso) and other clinical-stage competitors.
Binary clinical trial risk associated with the upcoming mid-2026 FURVENT Phase 3 data readout.

Thesis Invalidation Triggers

Failure of the Phase 3 FURVENT trial to meet its primary endpoint of progression-free survival (PFS).
Severe or unexpected adverse safety signals emerging from the firmonertinib clinical program.
Significant delays in patient enrollment for the ALPACCA Phase 3 trial or clinical holds on the ADC pipeline.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.